Search

Your search keyword '"Angelico, M"' showing total 53 results

Search Constraints

Start Over You searched for: Author "Angelico, M" Remove constraint Author: "Angelico, M" Topic medicine Remove constraint Topic: medicine
53 results on '"Angelico, M"'

Search Results

1. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

2. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

3. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

4. Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation

5. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

6. Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study

7. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

8. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

9. A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a 'Blended Principle Model'

10. Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry

11. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients

12. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

13. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

14. Hepatitis B-core Antibody Positive Donors in Liver Transplantation and Their Impact on Graft Survival: Evidence From The Liver Match Cohort Study

15. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

16. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

17. Patterns of chronic hepatitis B in Central Italy: a cross-sectional study

18. Treatment of chronic hepatitis B: recommendations from an Italian workshop

19. Liver transplantation in the presence of portal vein thrombosis: report from a single center

20. Pathogenesis and host response

21. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

22. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

23. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection

24. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

25. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

26. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

27. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study

28. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

29. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

30. HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome

31. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study

32. Skills and requirements of a transplant hepatologist: board certification of the Italian Association for the Study of the Liver (AISF)

33. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

34. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching

35. Outcomes of Liver Transplant for Adults With Wilson’s Disease

36. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation

37. A hyper-glycosylation of HBV surface antigen correlates with HBsAg-Negativity at immunosuppression-driven HBV reactivation in vivo and hinders HBsAg recognition in vitro

38. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial

39. HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets

40. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

41. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

42. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

43. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

44. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

45. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

46. VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE SETTING MAY REQUIRE UNCONVENTIONAL REGIMENS FOR RE-TREATMENT

47. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

48. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C

49. International comparison of liver transplant programmes: differences in indications, donor and recipient selection and outcome between Italy and UK

50. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

Catalog

Books, media, physical & digital resources